Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Chronic Myeloid Leukemia
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Leukemia (2148
)
Acute Myelogenous Leukemia (1005
)
Acute Lymphocytic Leukemia (417
)
Chronic Lymphocytic Leukemia (326
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (23
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
Leukemia (2148
)
Acute Myelogenous Leukemia (1005
)
Acute Lymphocytic Leukemia (417
)
Chronic Lymphocytic Leukemia (326
)
B Acute Lymphoblastic Leukemia (193
)
T Acute Lymphoblastic Leukemia (39
)
Childhood B Acute Lymphoblastic Leukemia (37
)
Hairy Cell Leukemia (23
)
Chronic Myelomonocytic Leukemia (20
)
Prolymphocytic Leukemia (17
)
Acute Promyelocytic Leukemia (12
)
Juvenile Myelomonocytic Leukemia (5
)
Chronic Eosinophilic Leukemia (4
)
Chronic Neutrophilic Leukemia (3
)
›
Associations
(267)
News
Trials
Search handles
@AaronGoodman33
@AlkaliDr
@Anand_88_Patel
@BldCancerDoc
@DrHKantarjian
@FadiHaddad_MD
@TalhaBadarMD
@jayastuMD
@jvalentingg
@tmprowell
Search handles
@AaronGoodman33
@AlkaliDr
@Anand_88_Patel
@BldCancerDoc
@DrHKantarjian
@FadiHaddad_MD
@TalhaBadarMD
@jayastuMD
@jvalentingg
@tmprowell
Filter by
Latest
9ms
Negative MRD by NGS is more sensitive than PCR, it indicates the absence of disease (at 10-6). The PCR positivity indicates the presence of BCR::ABL1 in the non-leukemia cells (CML-like biology). Those patients are in remission & just maintain TKI here. No need for CAR-T or HSCT (@FadiHaddad_MD)
9 months ago
Clinical • Next-generation sequencing
|
ABL1 (ABL proto-oncogene 1)
9ms
Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient https://t.co/dlELyRGPy9 @eskazanae @OncoAlert (@JournalCancer)
9 months ago
Clinical
9ms
Episode 2: Evolving Research in the Field of Chronic Myeloid Leukemia - Medscape - #CML #LMC @cmlnet @icmlf @mjmauroMD #EhabAtallah https://t.co/ytfWxiyuh8 #GoogleAlerts (@LMC_PACIENTES)
9 months ago
9ms
Episode 1: Chronic Myeloid Leukemia Therapy and the Mark Cuban Effect - Medscape - @cmlnet @icmlf @mjmauroMD https://t.co/3D7Jlt7apl #GoogleAlerts (@LMC_PACIENTES)
9 months ago
9ms
.@Dr_AmerZeidan of @SmilowCancer & @YaleCancer is leading clinical study EA9171, testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia could help patients. Learn more: https://t.co/tVmctb34sS #CML #leusm (@eaonc)
9 months ago
Clinical
9ms
Day 4 - blina + ponatinib in Ph+ acute leukemia w/ focus on CML lymphoid blast phase (n=6) -2 pt w/ de novo dz, 2 w/ untreated CML-BP w/ prev TKI, 2 w/ prev treated CML-BP -response in 5/6 pt -CMR in 2/6 pt -3 pt with subsequent relapse https://t.co/2q2V8sHPMF (@Anand_88_Patel)
9 months ago
Iclusig (ponatinib)
10ms
I am the living example that 50mg works great for me ! Thanks to all that dedicate their life to discover newer ways to get to better quality life for CML patients. I have a complete regular life thanks to the great care of my doctors in Dallas ! (@Josemenendez4)
10 months ago
Clinical
10ms
🚨join us tomorrow for an interesting discussion on #CML diagnostics, treatment and progression Link 👉 https://t.co/LvNIym1Bsg #cml #leukaemia #frontlinegenomics @FadiHaddad_MD (@horne_gillian)
10 months ago
10ms
#EHA23 Encouraging results of blinatumomab/ponatinib from @MDAndersonNews @NicholasShortMD @DrHKantarjian @NitinJainMD CR/CRi rates: ➡️ 92% in R/R Ph+ ALL ➡️ 86% in CML-LBP ➡️ Favorable safety profile #ALLsm #leusm @ALL_Hub_ #leukemia #endcancer (@FadiHaddad_MD)
10 months ago
Clinical
|
Iclusig (ponatinib) • Blincyto (blinatumomab)
10ms
.@Dr_AmerZeidan of @SmilowCancer & @YaleCancer is leading clinical study EA9171, testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia could help patients. Learn more: https://t.co/tVmctb34sS #CML #leusm (@eaonc)
10 months ago
Clinical
10ms
Data from Nikola Čuřík confirm that combination treatment with Asciminib and Ponatinib is the most attractive combination strategy for #CML high risk pts. @icml @espGELMC @EHA_Hematology #EHA23 (@jvalentingg)
10 months ago
Clinical
|
Iclusig (ponatinib) • Scemblix (asciminib)
10ms
Dr Cuenca Zamora from @crh_MoralesIMIB present data on behalf of @espGELMC regarding “MECHANISMS OF TROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TREATMENT WITH PONATINIB AND OTHER TYROSINE KINASE INHIBITORS” #EHA23 (@jvalentingg)
10 months ago
Clinical
|
Iclusig (ponatinib)
10ms
It is all because of the name. Nobody has any doubt that chronic myeloid leukemia is a cancer. As is chronic lymphocytic leukemia. But MDS, Polycythemia Vera and Myelofibrosis have strange names that no one readily associates with cancer. (@fabiopss)
10 months ago
10ms
CONGRESS | #ASCO23 | @RoloffGreg @uchicagoleuk presented a phase I study of selumetinib plus azacitidine in pts with high-risk chronic myeloid neoplasms. Eligibility: pts with higher risk MDS, MDS/MPNs, and myelofibrosis. Planned enrolment ~18 participants #MDSsm #medicalcongress (@MDS_Hub)
10 months ago
Clinical • P1 data
|
Koselugo (selumetinib) • azacitidine
10ms
#ClinicalTrial EA9171, led by @Dr_AmerZeidan of @SmilowCancer & @YaleCancer, is testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia will shrink the cancer or prevent it from returning. Learn more: https://t.co/tVmctb34sS #CML #leusm (@eaonc)
10 months ago
Clinical
10ms
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia https://t.co/0MJllt15hd #CML #scRNAseq @BloodJournal (@TalhaBadarMD)
10 months ago
imatinib
10ms
https://t.co/1taZrhA1gA: Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries. ➡️ Imatinib failure rate 15% #ASCO23 (@TalhaBadarMD)
10 months ago
Clinical
|
imatinib
10ms
👨🏻⚕️ Wonderful fellow's lecture by Asst Prof @FadiHaddad_MD discussing the latest developments in Advanced Phase CML ➡️ Check out our reviews in @LeukemiaJnl https://t.co/UnzDpPCg4n and @Cancers_MDPI https://t.co/YF0hcEGPpx on this challenging topic. @MDAndersonNews (@jayastuMD)
10 months ago
Metastases
10ms
3 Follicular lymphoma In acut promyelocytic leukemia there is bruising easily and bleeding gum In CLL there is anaemia and Bleeding or bruising In Mental cell there is tonsils enlargement and hepatomegaly In CML patient having a high temperature, and feeling hot or shivery (@kissinger_Mo)
10 months ago
Clinical
10ms
#bigdataforbloodcancer: Watch @AndreasHochhaus of Jena University Hospital @UKJ_Jena and @icmlf share his view on how cooperation can help address the open questions in #CML #research much faster. #hematology #bigdata #bloodcancerresearch - Chronic Myeloid #Leukaemia #leukemia (@HarmonynetEU)
10 months ago
Clinical
11ms
#ClinicalTrial EA9171, led by @Dr_AmerZeidan of @SmilowCancer & @YaleCancer, is testing if adding a new drug to the usual treatment for chronic myelogenous #leukemia will shrink the cancer or prevent it from returning. Learn more: https://t.co/tVmctb34sS #CML #leusm (@eaonc)
11 months ago
Clinical
11ms
I am honored to co-chair the chronic myeloid leukemia (CML) session at the upcoming International Congress on Leukemia Lymphoma Myeloma with dear Dr. Elisabetta Abruzzese, which will be held virtually on May 12-13, 2023 🤓😎🤗 #CML #CMLsm #leusm ➡️ https://t.co/gm2pmkJEvd (@eskazanae)
11 months ago
1year
The final session from the 2023 ‘Controversies in Hematologic Malignancies’ brought exciting glimpses into the future of FLT3-mutated AML and advanced-stage CML therapy. @PratzKW @MWDeininger @mcw_oncology @BloodResearchWI (@ksbcarlson)
1 year ago
Metastases
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3 mutation
1year
50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
1year
#CML with no MMR after 2 years of TKI is not adverse. Favorable outcomes are seen even with BCR::ABL 1-10% @AbidikianMD @MDAndersonNews #Leukemia https://t.co/KI5q4fmkT5 via @AjHematology #leusm (@DrHKantarjian)
1 year ago
ABL1 (ABL proto-oncogene 1)
1year
R/R Relapsed/Refractory Blinatumomab Inotuzumab ozogamicin (InO) Ponatinib multi-target kinase inhibitor-primary Bcr-Abl tyrosine kinase protein constitutively active ⬆️CML progression - fused Bcr / Abl gene- ▶️ Philadelphia chromosome Venetoclax B-cell lymphoma-2 (BCL-2)⬇️🕴🏿 (@RajaNatarajanS1)
1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
over1year
Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML @ASH_hematology #mpnsm #ASH22 https://t.co/d4GwbtyWaV (@OncLive)
over 1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
|
Nailike (olverembatinib)
over1year
Gene rearrangements found in 21 out 48 pts with r/r #CML. Secondary fusion proteins as a mechanism of BCR::ABL1 kinase‐independent resistance in chronic myeloid leukaemia https://t.co/fy9WFMrkBM (@AlkaliDr)
over 1 year ago
Clinical
|
ABL1 (ABL proto-oncogene 1)
over1year
NGS results in progressive #CML 👉🏻 accelerated phase: ASXL1 mutations 👉🏻 blast phase : RUNX1 mutations Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia | Blood Cancer Journal https://t.co/1MH4PalF1c (@AlkaliDr)
over 1 year ago
Next-generation sequencing
|
RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1)
|
RUNX1 mutation • ASXL1 mutation
over1year
Another poster of AST - Argentina stop trial at ESH John Goldman Conference Subset analysis of IL6 and IL2 plasma levels at the time of discontinuation identify CML patients who fail to sustain TFR # Teamwork #Biancavasconcelos @Fundaleu @beaLMC (@CaroPavlovsky)
over 1 year ago
Clinical
|
IL6 (Interleukin 6) • IL2 (Interleukin 2)
over1year
Bone Marrow Fibrosis + Splenomegaly DDx! Primary myelofibrosis = JAK2/CALR/MPL Hairy cell leukemia = BRAF V600E TAFRO = Castleman dz subtype Gaucher = ⬇️glucocerebrosidase Kala-azar (visceral leishmania) Gray platelet = NBEAL2 AIDS Renal osteodystrophy Some CML (@AaronGoodman33)
over 1 year ago
BRAF (B-raf proto-oncogene) • JAK2 (Janus kinase 2) • CALR (Calreticulin)
|
BRAF V600E • BRAF V600
over1year
Chronic myelogenous leukaemia, BCR-ABL +ve, continuous phase. (@CallingDrP)
over 1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
over1year
50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
over 1 year ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
almost2years
Chronic Myeloid Leukemia, specifically polycythemia rubra vera (JAK2) with focal hepatic ischaemia and infarction due to the hypercoagulable state. The liver ischaemia explains the liver function test changes. (@Uvini_SD)
almost 2 years ago
JAK2 (Janus kinase 2)
almost2years
Progress! After BCR-ABL1 that was detected but not enough to quantify my hematologist agreed to reduce my nightly dosage of #imatinib to 200 mg. I pray it works. #cml @CMLSupportGroup @cmlnet @LLSusa #Cancersucks (@espwapouJacmel)
almost 2 years ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
almost2years
Malignant Neutrophilia! Netrophilia + BCR-ABL p210 = CML BCR-ABL p230 = CML Lots of neutrophils! Not chronic neutrophilic leukemia ( which has CSF3R utation) CSF3R mutation = CNL Nuetrophilia minimal dysplasia ASXL1, NRAS, SETBP1, SRSF2 and TET2 = Atypical CML Dysplasia (@AaronGoodman33)
almost 2 years ago
ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCR (BCR Activator Of RhoGEF And GTPase) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • CSF3R (Colony Stimulating Factor 3 Receptor) • SETBP1 (SET Binding Protein 1)
almost2years
HPI: 50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
almost 2 years ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
2years
CML patients with high risk mutations do well with #BMT - disease control more important than presence of mutations The clinical significance of BCR-ABL1 mutations in patients with Ph+ chronic myeloid leukemia who underwent allo HCT @ASTCT_Journal #leusm https://t.co/maJgRSz9jg (@BldCancerDoc)
2 years ago
Clinical
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
BCR-ABL1 mutation
2years
STAMPing on BCR-ABL1: Asciminib Approved for Chronic Myeloid Leukemia | The Hematologist | American Society of Hematology. #CML @icmlf @espGELMC @Aelemic https://t.co/rgtwrFYt58 (@jvalentingg)
2 years ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
Scemblix (asciminib)
2years
over 1000 reads and one citation to date 🤓😎 Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia @tandfmedicine @tandfonline #CML #leusm https://t.co/gUuXa8r3BU (@eskazanae)
2 years ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
over2years
50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
over 2 years ago
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
|
imatinib
over2years
Read up on the latest progress bringing Asciminib and BCR-ABL1 inhibition to patients with chronic myeloid leukemia. @betulibiss and co review the Phase III ASCEMBL trial, current #RWE and ongoing clinical trials. 📖 - https://t.co/2P00mjecgm @eskazanae #MPNsm #LEUsm #Leukemia (@FutureOncol_FSG)
over 2 years ago
Clinical • Review
|
BCR (BCR Activator Of RhoGEF And GTPase)
|
Scemblix (asciminib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login